Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06827990 · ClinicalTrials.gov registry record · NA
GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections
A NA study of Aortic Dissection, sponsored by W.L.Gore & Associates.
- Recruiting
- Registry status
- NA
- Development phase
- 112
- Enrollment target
- 13
- Study locations
NCT06827990: Recruiting NA study of Aortic Dissection, sponsored by W.L.Gore & Associates.
NCT06827990 is a NA study of Aortic Dissection that is actively recruiting participants, run by W.L.Gore & Associates. The registered enrollment target is 112 participants, below the 654-participant average among 11 other Aortic Dissection trials with a reported enrollment target (83% lower). The trial reports 13 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06827990, a NA study of Aortic Dissection, is actively recruiting participants, sponsored by W.L.Gore & Associates.
- RECRUITING
- Registry status
- NA
- Development phase
- 112 participants
- Enrollment target
- 13
- Study locations
Study Summary
To assess the safety and effectiveness of the ASG device in the treatment of de novo Type A aortic dissections.
Primary Outcome
Composite of the following events: Death ≤30 days of the index endovascular procedure, or during initial hospitalization, whichever is later Disabling Stroke ≤30 days following the index endovascular procedure
Conditions Studied
Interventions
- DEVICE GORE® Ascending Stent Graft (ASG device)
Study Locations (13)
Ohio
- Cleveland Clinic - Cleveland
- Ohio Health Research Institute - Columbus
Texas
- The Methodist Hospital Houston - Houston
- Baylor Research Institute - Plano
Alabama
- University of Alabama at Birmingham - Birmingham
Florida
- University of Florida - Gainesville
Georgia
- Emory University School of Medicine - Atlanta
Illinois
- Northwestern Medicine - Chicago
Indiana
- Indiana University - Indianapolis
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2025-09-22 |
| Est. Completion | 2031-09-01 |
| Phase | NA |
What NCT06827990 shows while recruiting
NCT06827990 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 654-participant average among 11 other Aortic Dissection trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Aortic Dissection appearing as the primary indexed condition, and to 1 intervention - of which GORE® Ascending Stent Graft (ASG device) is the first listed.
NCT06827990 lists 13 locations in 11 states (Ohio, Texas, Alabama).
Frequently Asked Questions
What is clinical trial NCT06827990 about?
NCT06827990 is a clinical study titled "GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections". To assess the safety and effectiveness of the ASG device in the treatment of de novo Type A aortic dissections.
What is the current status of trial NCT06827990?
This trial is currently recruiting. It is a NA study. The enrollment target is 112 participants. The study started on 2025-09-22. Estimated completion is 2031-09-01.
What conditions does trial NCT06827990 study?
This clinical trial studies the following conditions: Aortic Dissection.
What interventions are being tested in trial NCT06827990?
The interventions under investigation include: GORE® Ascending Stent Graft (ASG device) (DEVICE).
Who is sponsoring clinical trial NCT06827990?
This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06827990 being conducted?
This trial has 13 study locations across Alabama, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aortic Dissection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06827990's enrollment target sits among peer trials
112 8th of 11 higher than 4 of 11 other Aortic Dissection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Aortic Dissection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
B-SAFER: Branched Stented Anastomosis Frozen Elephant Trunk Repair
RECRUITING · NA
-
Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies
RECRUITING · NA
-
Feasibility of Endovascular Repair Of Ascending Aortic Pathologies
RECRUITING · NA
-
NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness
RECRUITING · NA
-
Safety and Efficacy of Endovascular Repair of Complex Aortic Pathology With Physician-modified Endovascular Grafts (PMEGs)
RECRUITING · NA
-
Study to Evaluate the Clinical Performance of the Valiant Thoracic Stent Graft With the Captivia Delivery System (Valiant Captivia) for the Treatment of Acute, Complicated Type B Aortic Dissections
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI